Abstract
A microencapsulated, cell-based IL2 cytokine factory was recently developed, and the safety and efficacy of this platform in a mouse model of mesothelioma were demonstrated. This platform has the potential to overcome current challenges in the delivery of therapeutic cytokines for cancer immunotherapy.
Cite
CITATION STYLE
APA
Palanki, R., Swingle, K. L., & Mitchell, M. J. (2022). A (Controlled) Spill of IL2 for Localized Treatment of Mesothelioma. Clinical Cancer Research, 28(23), 5010–5012. https://doi.org/10.1158/1078-0432.CCR-22-2626
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free